Logo image of IMVT

IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD

20.02  +0.5 (+2.56%)

After market: 20.02 0 (0%)

Fundamental Rating

3

IMVT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While IMVT has a great health rating, there are worries on its profitability. IMVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMVT has reported negative net income.
In the past year IMVT has reported a negative cash flow from operations.
IMVT had negative earnings in each of the past 5 years.
IMVT had a negative operating cash flow in each of the past 5 years.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IMVT has a worse Return On Assets (-90.92%) than 71.85% of its industry peers.
IMVT's Return On Equity of -108.53% is in line compared to the rest of the industry. IMVT outperforms 43.18% of its industry peers.
Industry RankSector Rank
ROA -90.92%
ROE -108.53%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-41.61%
ROE(3y)-44.51%
ROE(5y)-46.31%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IMVT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for IMVT has been increased compared to 1 year ago.
IMVT has more shares outstanding than it did 5 years ago.
IMVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IMVT has an Altman-Z score of 23.90. This indicates that IMVT is financially healthy and has little risk of bankruptcy at the moment.
IMVT's Altman-Z score of 23.90 is amongst the best of the industry. IMVT outperforms 94.76% of its industry peers.
IMVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.9
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.04 indicates that IMVT has no problem at all paying its short term obligations.
IMVT has a better Current ratio (6.04) than 62.76% of its industry peers.
IMVT has a Quick Ratio of 6.04. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
IMVT has a Quick ratio of 6.04. This is in the better half of the industry: IMVT outperforms 63.11% of its industry peers.
Industry RankSector Rank
Current Ratio 6.04
Quick Ratio 6.04
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IMVT have decreased strongly by -42.39% in the last year.
EPS 1Y (TTM)-42.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.11% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-52.4%
EPS Next 2Y-26.55%
EPS Next 3Y-16.92%
EPS Next 5Y12.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMVT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as IMVT's earnings are expected to decrease with -16.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.55%
EPS Next 3Y-16.92%

More info and screens

0

5. Dividend

5.1 Amount

IMVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOVANT INC

NASDAQ:IMVT (3/7/2025, 8:00:02 PM)

After market: 20.02 0 (0%)

20.02

+0.5 (+2.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2025-02-06/bmo
Earnings (Next)05-30 2025-05-30/amc
Inst Owners46.52%
Inst Owner Change4.51%
Ins Owners1.41%
Ins Owner Change16.79%
Market Cap3.40B
Analysts86
Price Target47.31 (136.31%)
Short Float %21.62%
Short Ratio11.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.48%
Min EPS beat(2)-21.51%
Max EPS beat(2)0.54%
EPS beat(4)1
Avg EPS beat(4)-13%
Min EPS beat(4)-21.51%
Max EPS beat(4)0.54%
EPS beat(8)3
Avg EPS beat(8)-7.27%
EPS beat(12)4
Avg EPS beat(12)-6.52%
EPS beat(16)6
Avg EPS beat(16)-5.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.4%
PT rev (3m)-5.75%
EPS NQ rev (1m)6.41%
EPS NQ rev (3m)-3.91%
EPS NY rev (1m)0.5%
EPS NY rev (3m)-1.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.64
P/tB 9.64
EV/EBITDA N/A
EPS(TTM)-2.62
EYN/A
EPS(NY)-3.04
Fwd EYN/A
FCF(TTM)-1.92
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS0
BVpS2.08
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.92%
ROE -108.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-41.61%
ROE(3y)-44.51%
ROE(5y)-46.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.04
Quick Ratio 6.04
Altman-Z 23.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)151.14%
Cap/Depr(5y)180.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
EPS Next Y-52.4%
EPS Next 2Y-26.55%
EPS Next 3Y-16.92%
EPS Next 5Y12.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-59.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.92%
EBIT Next 3Y-29.75%
EBIT Next 5YN/A
FCF growth 1Y-96.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.51%
OCF growth 3YN/A
OCF growth 5YN/A